These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 15698532

  • 21. Safety evaluation to support First-In-Man investigations I: kinetic and safety pharmacology studies.
    Baldrick P.
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):230-6. PubMed ID: 18501489
    [Abstract] [Full Text] [Related]

  • 22. Single dose toxicity and repeated dose toxicity studies: introductory remarks.
    Kurokawa Y, Matsuzawa T.
    J Toxicol Sci; 1996 Dec; 21(5):413-6. PubMed ID: 9035047
    [No Abstract] [Full Text] [Related]

  • 23. Opportunities to minimise animal use in pharmaceutical regulatory general toxicology: a cross-company review.
    Sparrow SS, Robinson S, Bolam S, Bruce C, Danks A, Everett D, Fulcher S, Hill RE, Palmer H, Scott EW, Chapman KL.
    Regul Toxicol Pharmacol; 2011 Nov; 61(2):222-9. PubMed ID: 21855593
    [Abstract] [Full Text] [Related]

  • 24. How omics technologies can contribute to the '3R' principles by introducing new strategies in animal testing.
    Kroeger M.
    Trends Biotechnol; 2006 Aug; 24(8):343-6. PubMed ID: 16782220
    [Abstract] [Full Text] [Related]

  • 25. Race is on to find alternative to animal tests.
    Goodman S.
    Nature; 2002 Jul 11; 418(6894):116. PubMed ID: 12110854
    [No Abstract] [Full Text] [Related]

  • 26. A search to predict potential for drug-induced cardiovascular toxicity.
    Hamlin RL.
    Toxicol Pathol; 2006 Jul 11; 34(1):75-80. PubMed ID: 16507547
    [Abstract] [Full Text] [Related]

  • 27. Strategic focus on 3R principles reveals major reductions in the use of animals in pharmaceutical toxicity testing.
    Törnqvist E, Annas A, Granath B, Jalkesten E, Cotgreave I, Öberg M.
    PLoS One; 2014 Jul 11; 9(7):e101638. PubMed ID: 25054864
    [Abstract] [Full Text] [Related]

  • 28. Immune function tests for hazard identification: a paradigm shift in drug development.
    Gore ER.
    Basic Clin Pharmacol Toxicol; 2006 Apr 11; 98(4):331-5. PubMed ID: 16623854
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Direct dosing of preweaning rodents in toxicity testing and research: deliberations of an ILSI RSI Expert Working Group.
    Moser VC, Walls I, Zoetis T.
    Int J Toxicol; 2005 Apr 11; 24(2):87-94. PubMed ID: 16036767
    [Abstract] [Full Text] [Related]

  • 31. Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations.
    Bailey J, Balls M.
    BMC Med Ethics; 2019 Mar 01; 20(1):16. PubMed ID: 30823899
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Refinement, reduction, and replacement of animal use for regulatory testing: future improvements and implementation within the regulatory framework.
    Richmond J.
    ILAR J; 2002 Mar 01; 43 Suppl():S63-8. PubMed ID: 12388854
    [Abstract] [Full Text] [Related]

  • 34. Inbred strains should replace outbred stocks in toxicology, safety testing, and drug development.
    Festing MF.
    Toxicol Pathol; 2010 Aug 01; 38(5):681-90. PubMed ID: 20562325
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Humane science finds sharper and kinder tools.
    Stokstad E.
    Science; 1999 Nov 05; 286(5442):1068-71. PubMed ID: 10610517
    [No Abstract] [Full Text] [Related]

  • 38. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H, Narayanan P, Nims R.
    J Appl Toxicol; 2010 Jul 05; 30(5):387-96. PubMed ID: 20589744
    [Abstract] [Full Text] [Related]

  • 39. Introduction to special issue on developmental and reproductive toxicity study designs for pharmaceuticals.
    Wise LD.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec 05; 86(6):417. PubMed ID: 20025037
    [No Abstract] [Full Text] [Related]

  • 40. Animal experimentation: a rational approach towards drug development.
    Kumar V, Singh PN, Mishra B.
    Indian J Exp Biol; 2000 Jun 05; 38(6):540-8. PubMed ID: 11116523
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.